On the Role of c-Jun in the Induction of PAI-1 Gene Expression by Phorbol Ester, Serum, and IL-1α in HepG2 Cells
- 1 January 1999
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 19 (1) , 39-46
- https://doi.org/10.1161/01.atv.19.1.39
Abstract
—We have characterized the regulation of plasminogen activator inhibitor-1 (PAI-1) gene expression by phorbol 12-myristate 13-acetate (PMA), serum, and interleukin-1α (IL-1α) in the human hepatoma cell line HepG2. PMA, serum, and IL-1α induced a rapid and transient 28-fold (PMA), 9-fold (serum), and 23-fold (IL-1α) increase in PAI-1 mRNA, peaking after ≈4 hours. These inductions of PAI-1 mRNA accumulation were reduced by pretreatment of the HepG2 cells with the protein tyrosine kinase inhibitor genistein. Conversely, stimulation of tyrosine phosphorylation by sodium orthovanadate, an inhibitor of protein tyrosine phosphatases, caused an increase in PAI-1 mRNA levels. The effects of PMA, serum, and IL-1α on PAI-1 mRNA expression have been compared with their ability to modulate the expression of a chloramphenicol acetyltransferase (CAT) reporter plasmid, which was under control of the −489 to +75 region of the PAI-1 promoter, and stably transfected into HepG2 cells. This region of the PAI-1 promoter was previously found to contain a tetradecanoyl phorbol acetate–response element (TRE; between −58 and −50) necessary for PMA responsiveness and with a high affinity for c-Jun homodimers. Whereas incubation of these transfected HepG2 cells with PMA and serum showed an induction profile of CAT mRNA similar to that of PAI-1 mRNA, hardly any induction of CAT mRNA was found with IL-1α. In line with these findings, IL-1α poorly induced c-Jun homodimer binding to the PAI-1 TRE in gel mobility-shift assays. Pretreatment of HepG2 cells with the protein kinase C inhibitor Ro 31-8220 or the mitogen-activated protein kinase kinase (MAPKK) 1,2 activity blocker PD98059 selectively suppressed the induction of PAI-1 (and CAT) expression by PMA, but not that by IL-1α. In contrast, the protein tyrosine kinase inhibitor herbimycin A blocked PAI-1 mRNA induction by IL-1 α only. We propose 2 separate PAI-1 inductory pathways for PMA and IL-1α in HepG2, both involving protein tyrosine kinase activation; the serum-induced signaling pathway may (partially) overlap with the PMA-activated protein kinase C/mitogen-activated protein kinase kinase pathway, leading to c-Jun homodimer binding to the PAI-1 TRE.Keywords
This publication has 44 references indexed in Scilit:
- The search for physiological substrates of MAP and SAP kinases in mammalian cellsTrends in Cell Biology, 1997
- Role of C‐Jun and Proximal Phorbol 12‐Myristate‐13‐Acetate‐(PMA)‐Responsive Elements in the Regulation of Basal and PMA‐Stimulated Plasminogen‐Activator Inhibitor‐1 Gene Expression in HepG2European Journal of Biochemistry, 1996
- A common response element mediates differential effects of phorbol esters and forskolin on type‐1 plasminogen activator inhibitor gene expression in human breast carcinoma cellsEuropean Journal of Biochemistry, 1994
- Interleukin 1 induction of the c-jun promoter.Proceedings of the National Academy of Sciences, 1993
- Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states.Proceedings of the National Academy of Sciences, 1991
- Regulation of PAI-1 gene expressionFibrinolysis, 1991
- Plasminogen activator inhibitors: hormonally regulated serpinsMolecular and Cellular Endocrinology, 1990
- Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivoBlood, 1988
- Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factorCell, 1987
- Plasminogen activator inhibitorsBlood, 1987